Last reviewed · How we verify
Infusion of MSC
At a glance
| Generic name | Infusion of MSC |
|---|---|
| Sponsor | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy (PHASE2)
- To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). (PHASE3)
- A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome (PHASE1)
- Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment (PHASE1)
- Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI) (PHASE2)
- Autologous Stem Cell Therapy in Patients With Multiple System Atrophy (PHASE2)
- Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient (NA)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: